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ABSTRACT
A successful DNA vaccine for the treatment of tumors should break established 
immune tolerance to tumor antigen. However, due to the relatively low immunogenicity 
of DNA vaccines, compared to other kinds of vaccines using live virus or protein, a 
recombinant viral vector was used to enhance humoral and cellular immunity. In the 
current study, we sought to develop a novel anti-cancer agent as a complex of DNA 
and oncolytic adenovirus for the treatment of malignant melanoma in the C57BL/6 
mouse model. MART1, a human melanoma-specific tumor antigen, was used to induce 
an increased immune reaction, since a MART1-protective response is required to 
overcome immune tolerance to the melanoma antigen MelanA. Because GM-CSF is a 
potent inducer of anti-tumor immunity and TGF-β2 is involved in tumor survival and 
host immune suppression, mouse GM-CSF (mGM-CSF) and shRNA of mouse TGF-β2 
(shmTGF-β2) genes were delivered together with MART1 via oncolytic adenovirus. 
MART1 plasmid was also used for antigen-priming. To compare the anti-tumor effect 
of oncolytic adenovirus expressing both mGM-CSF and shmTGF-β2 (AdGshT) with that of 
oncolytic adenovirus expressing mGM-CSF only (AdG), each virus was intratumorally 
injected into melanoma-bearing C57BL/6 mice. As a result, mice that received AdGshT 
showed delayed tumor growth than those that received AdG. Heterologous prime-
boost immunization was combined with oncolytic AdGshT and MART1 expression to 
result in further delayed tumor growth. This regression is likely due to the following 
4 combinations: MART1-derived mouse melanoma antigen-specific immune reaction, 
immune stimulation by mGM-CSF/shmTGF-β2, tumor growth inhibition by shmTGF-β2, 
and tumor cell-specific lysis via an oncolytic adenovirus. Immune activation was 
mainly induced by mature tumor-infiltrating dendritic cell (TIDC) and lowered 
regulatory T cells in tumor-infiltrating lymphocytes (TIL). Taken together, these 
findings demonstrate that human MART1 induces a mouse melanoma antigen-specific 
immune reaction. In addition, the results also indicate that combination therapy of 
MART1 plasmid, together with an oncolytic adenovirus expressing MART1, mGM-CSF, 
and shmTGF-β2, is a promising candidate for the treatment of malignant melanoma.
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INTRODUCTION
The incidence of malignant melanoma is increasing 
worldwide [1], and is the fifth highest incidence among 
cancers in the US and the UK [2]. Although early primary 
melanomas can be cured surgically, this cancer can rapidly 
become fatal, following the development of metastasis. 
Therapeutic agents such as ipilimumab, which targets the 
cytotoxic T lymphocyte-associated protein 4 (CTLA4), 
and vemurafenib, which targets mutations that activate 
the B- Rapidly Accelerated Fibrosarcoma (RAF) gene, 
have previously been developed for malignant melanoma. 
However, while these agents take a short amount of 
time to respond to treatment, they lack high cure rates 
[3–6]. Therefore, the development of new treatments 
is inescapable, in order to improve the prognosis for 
malignant melanoma patients. In this study, granulocyte-
macrophage colony-stimulating factor (GM-CSF), 
shRNA against transforming growth factor-β (TGF-β), 
and melanoma antigen recognized by T cells 1 (MART1) 
were administered to mice to determine the effectiveness 
of immunotherapy as a complex form of DNA vaccine and 
armed oncolytic adenovirus on melanoma.
Some of the most potent inducers of anti-tumor 
immunity include the following: GM-CSF, a molecule 
that enhances immune responses by inducing proliferation, 
maturation, and migration of dendritic cells (DCs); 
expansion and differentiation of B and T lymphocytes; 
and direct recruitment of natural killer (NK) cells. On the 
contrary, GM-CSF is also known to enhance the expansion 
of myeloid derived suppressor cells (MDSC) [7]. The 
systemic use of recombinant GM-CSF is compromised by 
side effects, as well as the induction of potentially harmful 
MDSCs [8–10]. Furthermore, the efficacy of systemic 
recombinant GM-CSF treatment is limited, due to the 
presence of only a low local concentration of GM-CSF 
in tumors [11]. Therefore, local GM-CSF production by 
cancer cells could ensure a sufficient local concentration, 
while minimizing systemic exposure. This means GM-
CSF is an appealing molecule for local delivery to tumors, 
which would also be particularly useful in the context of 
oncolytic adenoviruses.
TGF-β signal plays important roles in tumor cell 
proliferation, differentiation, angiogenesis, collagen 
deposition, tumor invasion, and metastasis [12, 13]. In 
addition, TGF-β produced by cancer cells, or by stroma 
cells, stimulates MDSC to repress the immune response by 
certain cell types, including NK cells, DCs, macrophages, 
and T cells [7, 14]. The isoforms of TGF-β are TGF-β1, 
TGF-β2, and TGF-β3 [15]. While TGF-β1 is expressed 
in epithelial, endothelial, hematopoietic, and connective 
tissue cells, TGF-β2 is expressed in epithelial and neuronal 
cells, and TGF-β3 is expressed primarily in mesenchymal 
cells [16–18]. Specifically, TGF-β2 increases cytokine-
associated immunosuppression [19], antagonizes NK cells, 
lymphokine-activated killer (LAK) cells, and GM-CSF-
induced DC maturation [20–25], and contributes as a main 
activator of MDSC [26]. Thus, to stimulate the immune 
response efficiently with GM-CSF, TGF-β blockade is 
indispensable [23]. In addition, oncolytic viral infection of 
tumor cells induces the generation of anti-tumor immune 
responses via innate and adaptive anti-tumor immunity 
[27]. To boost anti-tumoral immunity, immunostimulatory 
cytokines, such as GM-CSF, have been loaded to 
oncolytic viruses [28–34]. In order to determine whether 
the anti-tumoral immunity of GM-CSF is enhanced by 
TGF-β inactivation by oncolytic viruses, we designed 
an oncolytic adenovirus expressing GM-CSF along with 
shRNA of TGF-β2 to examine the maximal anti-tumoral 
activity induced by optimal immune reaction. Blockade of 
TGF-β signaling also enhances tumor antigen-specific T 
cell activation [35], which provides a basis for the strong 
connection of TGF-β inhibition with immunization using 
tumor-specific antigen.
Plasmid DNA immunization has potential 
advantages, compared with traditional protein vaccination, 
as DNA induces strong cytotoxic T lymphocyte (CTL) and 
T helper 1 (Th1) responses, prolonged antigen expression, 
and resistance of the antigen source to antibody-mediated 
clearance [36–41]. To induce a mouse melanoma antigen-
specific immune response, we utilized MART1, a human 
melanocyte lineage-specific protein, which is expressed 
by 75–100% of melanomas but not by other cell or 
tumor types [42]. It has been speculated that activation of 
multiple immune pathways by antigens, delivered using 
different vectors, synergistically enhances the immune 
response to target antigens [43]. One approach that has 
proven to be particularly effective in eliciting a robust 
immune response is priming with plasmid DNA and 
boosting with a replication-incompetent adenovirus vector 
that encodes the same antigen [44].
In this study, we demonstrated prime-boost 
immunization by both DNA vaccine and oncolytic 
adenovirus, expressing that MART1, GM-CSF, and 
shRNA of TGF-β2 acting cooperatively induces both 
tumor-specific immune activation and general immune 
activation with oncolysis to have a pronounced anti-tumor 
effect.
RESULTS
Establishment of a mouse cell line with higher 
rate of adenoviral infection and replication
Compared with human cancer cells, most mouse 
cancer cells have lower infection efficiency with 
adenovirus, likely because mouse cells do not express the 
coxsackievirus and adenovirus receptor (CAR) [45, 46]. 
In addition, the replication rate of adenovirus is very low, 
which limits the effectiveness of oncolytic adenovirus 
in killing mouse cancer cells [47]. To overcome these 
limitations, the B16BL6-CAR/E1B55 mouse melanoma 
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cell line was developed [47]. This cell line expresses 
both the CAR and adenoviral E1B55 genes, and thus, 
exhibits enhanced infectivity by adenovirus (Figure 1A). 
The replication-dependent cytotoxic effects of adenovirus 
in B16BL6-CAR/E1B55 cells were quantitatively 
assessed using an in vitro cytopathic effect (CPE) assay. 
The replication of oncolytic adenovirus was induced in 
B16BL6-CAR/E1B55 cells in a multiplicity of infection 
(MOI)-dependent manner (Figure 1B, Left), and was 
clearly revealed in the in vitro cytopathic effect (CPE) 
assay (Figure 1B, Right). The expression of E1B-55KD 
protein in the structure of B16BL6-CAR/E1B55 was 
confirmed using newly produced E1B-55KD polyclonal 
antibody (Figure 1C).
TGF-β downregulation in melanoma cell
Real-time PCR confirmed the downregulation of 
TGF-β transcripts, induced by adenovirus expressing 
shRNA against mouse TGF-β1, TGF-β2, or both 
TGF-β1 and TGF-β2 in B16BL6-CAR/E1B55 cells. Five 
oligomers of TGF-β2 shRNA, as well as control shRNA 
(shRNA against scrambled sequence), were also validated 
using real-time PCR after selection of appropriate target 
sequences; in addition, the target sequence with maximal 
repression was identified. The target of TGF-β1 has 
been described previously [48]. As shown in Figure 
2A, among five validated TGF-β2 shRNAs (designated 
as TGF-β2 sh1–5), TGF-β2 sh3 elicited the greatest 
reduction of TGF-β2 mRNA levels (74%). To construct 
an oncolytic adenovirus, TGF-β shRNA sequences 
were inserted into the pSP72ΔE3-U6 (or H1) E3 shuttle 
vector to yield Ad-3484-CMVp-ΔE1B-U6-shmTGF-β1 
(Ad-shT1), Ad-3484-CMVp-ΔE1B-H1-shmTGF-β2 
(Ad-shT2), or Ad-3484-CMVp-ΔE1B-U6-shmTGF-β1-
H1-shmTGF-β2 (Ad-shT1+shT2). Ad-shT1 construct 
specifically decreased TGF-β1 mRNA levels, while Ad-
shT2 specifically decreased TGF-β2 mRNA levels (Figure 
2C, Left). Furthermore, the actual protein level of TGFβ1 
or TGFβ2 dowregulation by shRNA was also significantly 
decreased by the adenovirus that expressed shRNAs 
targeting TGF-β1 or TGF-β2, respectively (Figure 2C, 
Right). However, based on Figure 2D, downregulation 
of TGF-β isotype 2, other than isotype 1 or even both 
of isotypes 1 and 2, greatly reduced the cellular level of 
signaling molecules such as phospho-p65, phospho-Src, 
Figure 1: Infectivity of adenovirus in B16BL6-CAR/E1B55 cell line. A. A375 (human melanoma cell line), B16BL6 (mouse 
melanoma cell line), and B16BL6-CAR/E1B55 were infected with adenovirus-GFP at an MOI of 50. After 48 h, GFP expression was 
detected. B. The B16BL6-CAR/E1B55 cell line was infected with adenovirus-GFP at various MOIs (Left). To compare the oncolytic 
activity induced by Ad3484-CMVp-ΔE1B, cancer and normal cells were infected with each virus at an MOI of 1 to 20. When 293A cells 
infected with one of the viruses at an MOI of 1 exhibited complete cell lysis, all the remaining cells on the plate were fixed with 4% 
paraformaldehyde and stained with 0.5% crystal violet (Right). C. E1B-55K protein was detected by using E1B-55K polyclonal antiserum 
from one of selected clone of B16BL6-CAR-E1B55K cell line.
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Figure 2: Screening of mouse TGF-β2 and changes in signaling molecules by adenovirus expressing shmTGF-β. 
A. Screening of mouse TGF-β2 shRNAs. Sequences of shRNA oligomers targeting mouse TGF-β2 are shown with the selected target 
sequence indicated in bold (Top). The candidate oligomers for each target and the positive control shRNA were transfected into B16F10 
cells. The knockdown efficiency of each oligomer was measured using quantitative real-time PCR to amplify mouse TGF-β2. Relative 
expression levels of mouse TGF-β2 were plotted after normalization to the scrambled shRNA as a negative control (Bottom). B. Ad-
3484-CMVp-ΔE1B is a replication-competent adenovirus used as a control (Ad). This adenovirus contains the E1A gene controlled by the 
CMV promoter but lacks the E1B gene. Ad-3484-CMVp-ΔE1B-ΔE3-U6-shmTGF-β1 (Ad-shT1) and Ad-3484-CMVp-ΔE1B-ΔE3-H1-
shmTGF-β2 (Ad-shT2) are composed of the shmTGF-β1 or shmTGF-β2 genes in the E3 region of Ad-3484-CMVp-ΔE1B, respectively. 
Ad-3484-CMVp-ΔE1B-ΔE3-H1-shmTGFβ2-U6-shmTGF-β1 (Ad-sh1+shT2) is composed of the shmTGF-β1 and shmTGF-β2 genes 
in the E3 region of Ad-3484-CMVp-ΔE1B. C. Relative expression levels of mTGF-β1 and mTGF-β2 mRNA. Oncolytic Ad (Ad), Ad-
shTGFβ1 (Ad-shT1), Ad-shTGFβ2 (Ad-shT2), or Ad-shTGFβ1+shTGFβ2 (Ad-shT1+shT2) virus were injected into B16BL6-CAR/
E1B55 cells at an MOI of 100. The knockdown efficiency of these viruses was measured by quantitative real-time PCR of mTGF-β1 or 
mTGF-β2 (Left). Protein levels of mTGF-β1 and mTGF-β2. Oncolytic Ad (Ad), Ad-shTGFβ1 (Ad-shT1), Ad-shTGFβ2 (Ad-shT2), or Ad-
shTGFβ1+shTGFβ2 (Ad-shT1+shT2) virus were injected into B16BL6-CAR/E1B55 cells at an MOI of 100. The knockdown efficiency 
of these viruses was measured by ELISA of TGF-β1 (Right, top) or TGF-β2 (Right, bottom). D. B16BL6-CAR/E1B55 cells were injected 
with oncolytic Ad (Ad), Ad-shTGFβ1 (Ad-shT1), Ad-shTGFβ2 (Ad-shT2), or Ad-shTGFβ1+shTGFβ2 (AdshT1+shT2) virus at an MOI of 
100. Two days later, the endogenous expression levels of various signaling molecules were detected by western blot.
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N-cadherin and β-catenin which are involved in cancer 
cell survival and metastasis.
Development of oncolytic adenovirus expressing 
both mGM-CSF and shmTGF-β2
As shown in Figure 2D, downregulation of 
mTGF-β2, rather than mTGF-β1, clearly reduced the 
expression of survival/metastasis-promoting molecules. 
As a result, effective protection from tumor challenge was 
expected to be conferred by the combined treatment of 
mGM-CSF and shRNA against mTGF-β2. To develop the 
mGM-CSF-expressing recombinant oncolytic adenovirus, 
mGM-CSF gene was inserted into the E1 region of 
oncolytic adenovirus to yield AdG. In addition, AdGshT 
was generated as an oncolytic adenovirus, expressing 
both mGM-CSF and shRNA against mTGF-β2 (Figure 
3A). The oncolytic ability of these replication-competent 
adenoviruses was analyzed by an in vitro CPE assay of 
various cell lines (293A, B16BL6-CAR/E1B55, and 
NIH3T3 cells), after cells were infected with oncolytic Ad, 
AdG, or AdGshT at different MOIs. As shown in Figure 3B, 
all replication-competent adenoviruses induced increasing 
CPE in melanoma cells (B16BL6-CAR/E1B55), but not in 
normal cells (NIH3T3).
Oncolytic adenovirus expressing GM-CSF 
and shRNA of TGF-β delayed tumor growth 
concomitant with immune stimulation in a 
mouse model
To demonstrate the expression levels of both 
mGM-CSF and mTGF-β2, B16BL6-CAR/E1B55 cells 
were infected with AdGshT at an MOI of 50. Two days 
after infection, the cellular mRNA levels of mGM-CSF 
and mTGF-β2 were examined. A significant increase in 
the secreted amount of mGM-CSF (Figure 3C) and a 
significant reduction of mTGF-β2 mRNA levels (Figure 
3D) were observed. To confirm that an enhanced anti-
cancer immune response was induced by recombinant 
adenovirus expressing both mGM-CSF and shRNA 
against mTGF-β2, ex vivo and in vivo tests were 
performed. The cytotoxic activity of splenocytes against 
mouse melanoma cells, infected with various oncolytic 
Figure 3: Recombinant adenoviruses expressing mGM-CSF and shmTGF-β2. A. Schematic representation of adenovirus 
vectors expressing mGM-CSF and shmTGF-β2. Ad-3484-CMVp-ΔE1B-CMVp-mGM-CSF (AdG) is composed of the mGM-CSF gene in 
the E1 region, and Ad-3484-CMVp-ΔE1B-CMVp-mGM-CSF-ΔE3-H1-shmTGF-β2 (AdGshT) is composed of the shmTGF-β2 gene in the 
E3 region of Ad-3484-CMVp-ΔE1B. B. Oncolytic activity of these viruses was analyzed using an in vitro CPE assay. Cancer and normal 
cells were infected with each virus at an MOI of 0.1 to 50. To examine the level of mGM-CSF and mTGF-β2 mRNA expression, B16BL6-
CAR/E1B55 cells were infected with virus at a MOI of 50. Two days after injection, mGM-CSF expression levels were measured in the 
culture supernatants by ELISA C. and mTGF-β mRNA was estimated by RT-PCR D.
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adenovirus (AdG, AdshT, AdGshT), was measured with an 
lactate dehydrogenase (LDH) assay. The oncolytic Ad-
GMCSF-shTGFβ2-infected cells induced enhanced 
splenocyte anti-tumor activity, compared to cells infected 
with oncolytic Ad-GMCSF or Ad-shTGFβ2 only (Figure 
4A). To determine whether the same effects were induced 
in an animal model of melanoma, C57BL/6 mice were 
subcutaneously injected with B16BL6-CAR/E1B55 
melanoma cells. When tumors reached a range of 50–
60 mm3, mice were intratumorally injected with PBS, 
oncolytic Ad as a control (Ad), oncolytic Ad-GMCSF 
(AdG), or oncolytic Ad-GMCSF-shTGFβ2 (AdGshT) on 
days 1, 3, and 5. As shown in Figure 4B, control tumors 
that received PBS exhibited the fastest growth, and tumors 
infected with both oncolytic Ad and oncolytic Ad-GMCSF 
were even grown rapidly, while oncolytic Ad-GMCSF-
shTGFβ2 showed an effective delayed tumor growth. 
This enhanced anti-tumor effect was attributed to both the 
stimulation of a non-specific immune reaction by mGM-
CSF expression and the downregulation of mTGF-β2. 
However, meaningful tumor regression was not observed 
even in the oncolytic Ad-GMCSF-shTGFβ2-infected mice 
group.
To identify the types of infiltrating immune 
cells in tumor tissues, tumor sections were examined 
by immunohistochemistry using anti-CD4, anti-CD8, 
anti-NK1.1, or CD11b+c antibody for the detection of 
CD4+ T cell, CD8+ T cell, NK cell or NK T cell, and 
macrophage or dendritic cell, respectively (Figure 4C). As 
a result, infiltration of CD8+ T cells, CD4+ T cells, NK 
cells, and NK T cells in tumor tissues increased, after 
infection of oncolytic Ad-GMCSF-shTGFβ2, compared 
to the infection of oncolytic control adenovirus, but not 
significantly.
Figure 4: The anti-tumor effect of adenoviruses expressing mGM-CSF and shmTGF-β2. The anti-tumor effect of oncolytic 
Ad-GMCSF, Ad-shTGFβ2 or Ad-GMCSF-shTGFβ2 was confirmed by ex vivo (A) and in vivo (B) experiments. A. B16BL6-CAR/E1B55 
cells infected with each virus at an MOI of 50 were incubated with splenocytes isolated from 3 mice of each group of C57BL/6 for 4 h. The 
splenocyte cytotoxic activity was measured by an LDH assay. E:T means the ratio of total number of effector cells (splenocytes) to target 
cells (infected B16BL6-CAR/E1B55 cells). B. C57BL/6 tumor-bearing mice were treated with intratumoral injections of 1 × 109 PFU/50 
μL of adenoviruses on days 1, 3, and 5. Tumor volume was monitored and recorded every 2 days until the end of the study. Values represent 
the mean ± SE (5 animals per group)(Top). Overall survival was determined throughout a 15-day time course (Bottom). C. Representative 
immunohistochemical analysis of recombinant adenovirus infected tumor sections. 3 mice of each group of C57BL/6 tumor-bearing mice 
were treated with intratumoral injections of 1 × 109 PFU/50 μL of adenoviruses on days 1, 3, and 5. Tumors were collected at day 11 
for histological analysis. Paraffin- sections of tumor tissue were stained with anti-adenovirus type 5, anti-CD4, anti-CD8, anti-NK1.1 
antibodies, and anti-CD11b+c. The dark purple spots indicate.adenovirus type 5, CD4, CD8, NK/NKT and DC cells, respectively. NK1.1 
is a key marker of NK and NKT cells. CD11b is a key marker of macrophages and CD11c is a key marker of dendritic cells (Top). Results 
are given as the relative intensity of adenovirus type 5, CD4, CD8, NK/NKT and DC cells to PBS of each 3 mouse. Horizontal black bars 
indicate mean values (Bottom).
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Induction of mouse melanoma antigen-specific 
immune activity by human MART1 plasmid
Ribas et al. (2000) previously showed that DCs, 
that were genetically modified to express human MART1, 
generated murine MelanA-specific anti-tumor immune 
responses in a B16 melanoma model [49]. These findings 
imply that stimulation of MART1 will induce a MelanA-
specific immune response in our mouse melanoma model. 
We examined the endogenous level of MART1 or MelanA 
in various melanoma cell lines. MART1 was expressed in 
human melanoma cell lines (SK-MEL-2, SK-MEL-3, and 
SK-MEL-28), whereas murine MelanA, which has 68.8% 
homology with MART1 [49], was expressed in mouse 
melanoma cell lines (B16BL6 and B16F10), but not in 
mouse normal cells (NIH3T3; Figure 5A). Accordingly, 
we decided to use MART1 as a target of immune priming/
boosting for immunotherapy of melanoma. The expression 
of MART1 protein increased in MART1 plasmid-
transfected mouse melanoma cells, in a dose-dependent 
manner (Figure 5B). To induce immune activation, 50 μg 
(per 25 g of mouse) of MART1 plasmid in a total volume 
of 50 μl saline was injected intramuscularly into the rear 
quadriceps of C57BL/6 mice, since muscle cells injected 
with plasmid DNA produce large amounts of gene-
encoded protein [36, 50]. Injections of MART1 plasmid 
were given three times at one-week intervals. One week 
after the final injection, mice were sacrificed, and their 
spleens were removed. To determine the effect of immune 
priming by MART1, splenocytes were isolated, and 
spontaneous LDH release was measured after co-culture 
of the splenocytes with B16BL6 mouse melanoma cells. 
Cytotoxic activity of the splenocytes isolated from mice 
injected with MART1 plasmid was effectively enhanced, 
compared with that of the splenocytes isolated from mice 
injected with control plasmid (Figure 5C). Moreover, 
the enhancement of splenocyte cytotoxic activity was 
dependent on the ratio between effector cells (splenocytes) 
and target cells (B16BL6 cells) (Figure 5C, Left). The 
immune activation effect, which was induced by MART1 
plasmid treatment, was not observed in the Lewis lung 
carcinoma (LLC) cell line (Figure 5C, Right), which is a 
mouse lung cancer cell line that does not express MelanA. 
This result indicates that injection of human MART1 
plasmid primes mouse MelanA-specific immunity, as it 
induces the development of an immune cell population 
that is cross-reactive to both human MART-1 and mouse 
MelanA.
Figure 5: Effects of the human MART1 plasmid on mouse melanoma antigen-specific immune priming. A. MART1 and 
mMelanA expression was detected in various human and mouse melanoma cells (except NIH3T3 as a negative control) by western blot. 
B. MART1 translational levels were assessed in B16BL6 cells after transfection with pVAX1 or pVAX-MART1. C. Splenocytes were co-
cultured with B16BL6 or LLC cells for 4 h after collection from 4 mice of each group injected with control plasmid or MART1 plasmid. 
The cytotoxicity of splenocytes was then determined with an LDH assay.
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Development of adenovirus expressing MART1, 
GM-CSF, and shTGF-β2
In an attempt to produce stronger and longer-
lasting immune responses than those created by AdGshT, 
recombinant pVAX1-MART1 plasmid, and recombinant 
oncolytic adenovirus expressing MART1, mGM-CSF, and 
shRNA of mTGF-β2 were administered. Ad-3484-CMVp-
ΔE1B-MART1 (AdM) was constructed with the purpose 
of inducing mouse melanoma antigen-specific immune 
priming and boosting. Furthermore, Ad3484-CMVp-
ΔE1B-MART1-IRES-mGM-CSF-ΔE3-H1-shmTGF-β2 
(AdMGshT) was constructed in order to simultaneously 
enhance the mouse melanoma antigen-specific immune 
response, non-specific general immune response, and 
suppression of cancer cell growth. MART1 and mGM-
CSF, which were part of an internal ribosome entry site 
(IRES) expression cassette, were inserted into the E1 
region of adenovirus genome, while shmTGF-β2 was 
inserted into the E3 region (Figure 6A). The oncolytic 
activity of the recombinant adenoviruses was verified by 
an in vitro CPE assay (Figure 6B). Before progressing to 
animal tests to further investigate the anti-tumor effects 
of the AdMGshT, expressions of oncolytic adenovirus-
arming MART1, mGM-CSF and shmTGF-β2 genes were 
examined. B16BL6-CAR/E1B55 cells were infected with 
oncolytic control virus (Ad), oncolytic virus expressing 
MART1 (AdM), or oncolytic virus expressing MART1, 
GM-CSF, and shRNA of TGF-β2 (AdMGshT) at an MOI 
of 50. Two days after infection, MART1 protein was 
detected by western blotting, and the results showed a 
significant increase in the endogenous cellular levels 
of the virally transduced MART1 protein (Figure 6C, 
Left). Furthermore, MART1 protein, which is located 
on the surface of melanoma cells, was detected by flow 
cytometric analysis, and the surface expression of MART1 
Figure 6: Recombinant adenovirus vectors expressing MART1, mGM-CSF, and shmTGF-β2. A. Ad3484-CMVp-ΔE1B-
CMVp-MART1 (AdM) is composed of the MART1 gene in the E1 region of Ad3484-CMVp-ΔE1B. Ad3484-CMVp-ΔE1B-MART1-IRES-
mGM-CSF-ΔE3-H1-shmTGF-β2 (AdMGshT) is composed of the MART1 and mGM-CSF genes in the E1 region and shmTGF-β2 gene in the 
E3 region of Ad3484-CMVp-ΔE1B. B. The oncolytic activity of these viruses was analyzed by an in vitro CPE assay. Cancer and normal 
cells were infected with each virus at an MOI of 0.1 to 100. C. Left). B16BL6-CAR/E1B55 cells were infected with Ad, AdM, AdMGshT at 
an MOI of 50. Two days later, the endogenous expression level of MART1 was detected by western blot. MART1 cell-surface expression 
levels were also detected by flow cytometric analysis (C, Right). To examine mGM-CSF levels, B16BL6-CAR/E1B55 cells were infected 
with Ad, AdG, AdMGshT at a MOI of 50. Two days after injection, mGM-CSF expression levels were measured in the culture supernatants by 
ELISA D. To examine mTGF-β2 protein levels, B16BL6-CAR/E1B55 cells were infected with Ad, AdshT, AdMGshT at a MOI of 50. Two days 
after injection, mTGF-β2 protein levels were measured in the culture supernatants by ELISA E.
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increased on MART1 gene-containing virus-infected 
cells (Figure 6C, Right). To quantify the expression level 
of mGM-CSF induced by infection with recombinant 
adenovirus, B16BL6-CAR/E1B55 cells were infected with 
Adc, AdG, or AdMGshT virus at an MOI of 50. An enzyme-
linked immunosorbent assay (ELISA) was then performed 
to estimate the mGM-CSF protein concentration of cell 
supernatants. The mGMCSF gene-containing virus-
infected cells exhibited significantly increased secretion 
of the virally transduced mGM-CSF protein (Figure 6D), 
while the level of secreted mTGF-β2 protein significantly 
decreased in the shRNA of TGF-β2 gene-containing virus-
infected cells (Figure 6E).
Anti-tumor effect of MART1 plasmid with 
oncolytic adenovirus expressing GM-CSF and 
shRNA of TGF-β2
We expected that treatment with MART1 plasmid 
together with the oncolytic adenovirus expressing 
MART1, mGM-CSF, and shmTGF-β2 (AdMGshT) would 
generate a stronger anti-tumor effect against B16BL6-
CAR/E1B55 in vivo, as this method was designed to 
induce priming-boosting and stimulation of immunity 
and oncolysis. Figure 7A shows experimental conditions 
for the heterologous prime-boost immunization, designed 
to induce an anti-tumor effect using MART1 DNA and 
AdMGshT virus. As shown in Figure 7B, the growth rate 
of tumors in mice immunized with MART1 plasmid and 
Ad was slightly delayed than that in mice immunized 
with MART1 plasmid and PBS. In contrast, tumors of 
mice receiving both MART1 plasmid and AdMGshT had a 
significantly delayed growth rate compared to those of 
mice treated with either Ad, AdM or even AdGshT, although 
tumor regression was not induced (Figure 7B).
To analyze the infection rate of adenovirus vector 
and the infiltration of immune cells to tumor tissues 
following mouse injection with MART1 plasmid and 
adenovirus, we performed a histologic analysis of 
the tumor site. As shown in Figure 7C, many of the 
tumor tissues in mice injected with MART1 plasmid 
+ Ad, MART1 plasmid + AdM, or MART1 plasmid + 
AdMGshT displayed expression of adenovirus-specific 
protein, whereas mice in the PBS-treated group did 
not. Furthermore, in the mice that were immunized 
with MART1 plasmid + AdMGshT, many tumor tissues 
exhibited increased lymphocytic infiltration compared 
with that of the mice immunized with MART1 plasmid 
+ Ad or MART1 plasmid + AdM. To identify the types of 
immune cells that had infiltrated into the tumor tissues, 
tumor sections were examined by immunohistochemistry 
using anti-CD4, anti-CD8, anti-NK1.1 or anti-CD11b+c 
monoclonal antibodies. Slightly higher frequencies of 
CD8+ T cells, NK cells, NKT cells, dendritic cells and 
macrophages were observed in the tumors treated with 
MART1 plasmid + AdMGshT when compared to those 
of mice treated with MART1 plasmid + Ad or MART1 
plasmid + AdM (Figure 7C).
Enhanced infiltration of tumor tissues by both of 
T cells and dendritic cells after MART1 plasmid 
+ AdMGshT
To investigate further immune activation by MART1 
plasmid + AdMGshT, tumor-infiltrating or splenic immune 
cells were examined. As shown in Figure 7D, tumor-
infiltrating CD4+, CD8+ T and NKT cells increased after 
MART1 plasmid + AdMGshT, instead, tumor-infiltrating 
CD4+CD25+FoxP3+ regulatory T cells were decreased. 
However, elevated or decreased levels of corresponding 
immune cells were not significant in spleen. Then, we 
examined IFN-γ expression at the tumor site whether 
the tumor-infiltrating immune cells had higher immune 
activities depending on the combinations. Consequently, 
the highest concentration of IFN-γ was clearly observed 
in tumor tissue after treatment with MART1 plasmid + 
AdMGshT (Figure 7E). However, adenoviral production 
gradually decreased until after three weeks (Figure 7F). 
To more clearly distinguish the phenotype of tumor-
infiltrating dendritic cells (TIDCs), TIDCs were regarded 
as either mature dendritic cells by higher intensity 
CD11c+/lower intensity CD11b+, or tolerogenic dendritic 
cells by lower intensity CD11c+/higher intensity CD11b+. 
As shown in Figure 7G, virtually all of the CD11c+ TIDCs 
also co-expressed CD11b+ on their surfaces, as previously 
indicated by Berhanu et al. [51], and most dendritic cells 
were maturated after treatment with MART1 plasmid 
+ AdMGshT. Similar result was also obtained in CD4+ T 
cells, with decreasing amount of regulatory T cells after 
treatment with MART1 plasmid + AdMGshT (Figure 7H).
In summary, Figure 8 provides a schematic diagram 
of prime-boost immunization by both the DNA vaccine 
encoding human MART1, and the oncolytic adenovirus 
expressing MART1, GM-CSF and shRNA of TGF-β2. 
Heterologous immunization induces a stronger anti-tumor 
effect through enhanced immune activation and tumor cell 
lysis.
DISCUSSION
B16BL6 mouse melanoma cells express high 
levels of melanA; however, when these cells are injected 
into mice to induce tumor formation, the host immune 
tolerance to self-antigen (melanA) only permits a weak 
immune response to B16BL6 tumors [52]. To overcome 
this issue and induce an anti-B16BL6 tumor immune 
response, human MART1 plasmid was administered to 
mice as a DNA vaccine.
In this study, we evaluated the effectiveness 
of a prime-boost strategy in generating an antigen-
specific protective response against the murine MART1 
counterpart, which is endogenously expressed by murine 
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Figure 7: Anti-tumor effect of the combination treatment of MART1 plasmid with Ad, AdM, AdGshT, and AdMGshT. A. 
Diagram of the experimental design. C57BL/6 mice were injected with 7 × 105 B16BL6-CAR/E1B55 cells in 100 μL on day -5 and injected 
intramuscularly with 50 μg/50 μL of MART1 plasmid into the rear quadriceps on day -2. C57BL/6 tumor-bearing mice were treated with 
intratumoral injections of 1 × 109 PFU/50 μL of adenovirus on day 1, 3, and 5. B. Tumor volume was monitored and recorded every 2 days until 
the end of the study. Values represent the mean ± SE (5 animals per group) (Top, Left). Overall survival was determined throughout a 15-day 
time course (Top, Right). Photographs of C57BL/6 tumor-bearing mice treated with virus were obtained at day 11 after virus infection (Bottom). 
C. Representative immunohistochemical analysis of recombinant adenovirus-infected tumor sections was done as follows. 3 animals per group 
of C57BL/6 mice were injected with 7 × 105 B16BL6-CAR/E1B55 cells/100 μL on day -5 and then treated with intramuscular injections of 50 
μg/50 μL of MART1 plasmid into the rear quadriceps on day -2. C57BL/6 tumor-bearing mice were treated with intratumoral injections of 1 × 
109 PFU/50 μL of various kinds of adenovirus on day 1, 3, and 5. Tumors were collected at day 11 for histological analysis. Paraffin sections of 
tumor tissue were stained with anti-adenovirus type 5, anti-CD8, anti-CD4, anti-NK1.1, anti-CD11b+c (Top) Results are given as the relative 
intensity of adenovirus type 5, CD4, CD8, NK/NKT and DC cells to PBS of each 3 mouse. Horizontal black bars indicate mean values (Bottom).
(Continued )
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Figure 7 (Continued ): D. Flow cytometric analysis of various types of tumorigenic or splenic immune cells after combination treatment 
of MART1 plasmid with Ad or AdMGshT. 3 animals per group of mice bearing B16BL6-CAR/E1B55 cells were sacrificed and tumorigenic 
or splenic immune cells were isolated after combination treatment of MART1 plasmid with Ad or AdMGshT as indicated in detail in (A). To 
set the gate, T-cell gating of positive CD3 using Jurkat cell was performed. Each cell was then costained with anti-CD3 and anti-CD8 (or 
anti-CD4) for the detection of T cells. Otherwise, each cell was then costained with anti-NK1.1 and anti-CD122 after gating with anti-CD3 
and anti-NK1.1 for the detection of NKT cells or for the detection of regulatory T cells, each cell was then costained with anti-CD25 and 
anti-FOXP3 after gating with anti-CD4 and anti-CD25. Numbers in inset are percentage of cells in a given quadrant. All flow cytometric 
results are representative of three experiments (Left, Middle). Right results are the average percentage of corresponding immune cells in 
each 3 mouse. Horizontal black bars indicate mean values.
(Continued )
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Figure 7 (Continued ): E. Immunohistochemical analysis was performed as indicated in (C) by staining with anti-IFN-γ antibody (Left). 
Results are given as the relative intensity of IFN-γ to PBS of each 3 mouse. Horizontal black bars indicate mean values (Right). F. IHC 
using Ad5 antibody was performed to examine the residual adenovirus at the indicated day after infection of oncolytic control adenovirus 
was administered intratumorally (1 x 109 PFU per tumor in 50 μl of PBS) on days 1, 3, and 5. Representative confocal immunofluorescence 
staining of tumor sections was done as described in Materials and methods to confirm the increased mature TIDCs (G., green color) or 
decreased regulatory T cells (H., orange color) after combination treatment of MART1 plasmid with AdMGshT (Left). TIDC or regulatory 
T cells were counted on images taken from multiple fields per mouse (n = 3/group). Results are given as the average percentage of 
CD11bloCD11chi+ cells or CD4+CD25+ cells in each 3 mouse. Horizontal black bars indicate mean values (Right).
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melanoma B16BL6 cells, using plasmid DNA to express 
human MART1 antigen. The cross-species protective 
response may result from an epitope that is derived from 
the nearly 70% shared amino acid sequence or the 30% 
non-homologous amino acid sequence [49, 53]. The 
human MART1 sequence may contain peptides that 
efficiently bind to the C57BL/6 MHC class I molecules 
(H-2b) in muscle cells, and stimulate an effective response 
against murine MelanA expressed by B16BL6 cells [49]. 
To induce a stronger and longer-lived mouse melanoma 
antigen-specific immune response, the human MART1 
plasmid and the recombinant adenovirus vector expressing 
MART1 were administered to tumor-bearing mice. 
Moreover, non-specific immune stimulation was induced 
by expression of GM-CSF, and inhibition of tumor cell 
survival, growth, and immune evasion was induced by 
siRNA of TGF-β. In the present study, shRNAs were used 
to suppress TGF-β1 and TGF-β2 expression, as these 
two isoforms are expressed in the majority of malignant 
melanomas [54, 55]. Although suppression of TGF-β 
expression was expected to strongly inhibit tumor growth 
and survival, the reduction of signaling molecules related 
to cell growth, survival, and metastasis was modest after 
downregulation of TGF-β1; however, the silencing of 
TGF-β2 resulted in a much more pronounced reduction 
in expression of these downstream signaling molecules.
The most effective way of anti-tumor 
immune activation was heterologous immunization with 
MART1-GMCSF-shTGFβ2 combination. Consistent 
with its ability to increase or decrease tumor-infiltrating 
immune cells (Figure 7C, 7D), or increase IFN-γ secretion 
(Figure 7E) or increase significantly active dendritic cells 
and decrease regulatory T cells (Figure 7G, 7H), MART1 
and virus in AdMGshT treatment induced the greatest anti-
tumor effect in immunecompetent mouse-model system 
suitable for our oncolytic adenovirus. Intriguingly, 
Figure 8: Schematic heterologous prime-boost immunization regimen with various types of anti-tumor immunity. 
Human MART1 antigen presentation to mouse muscle cells injected with MART1 plasmid induces an antigen-specific immune response 
and MART1 antigen-specific memory T cells arise (priming). After MART1 plasmid injection, oncolytic adenovirus expressing MART1, 
mGM-CSF, and shmTGF-β2 were intratumorally injected (boosting). While the increased MART1 protein expression on tumor cells by 
adenovirus induces faster and stronger MART1-specific CD8+ and CD4+ T cell immune response, the adenovirus-mediated expression of 
mGM-CSF and suppression of TGF-β2 expression induce antigen-nonspecific activation of various immune cells. In this process, IFN-γ 
produced by active immune cells such as CD8+ T cells with the help of both of mature DCs and relieved regulatory T cells can trigger an 
anti-tumorigenic cytotoxicity. Furthermore, the oncolytic property of adenovirus induces viral replication in tumor cells and effective tumor 
cell lysis. Consequently, the virus can be released and re-infected surrounding tumor cells, and immune activation and tumor cell lysis are 
then repetitively induced by the virus.
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increases of splenic immune cells such as CD4+, CD8+ T 
and NKT cells or decrease of splenic CD4+CD25+FoxP3+ 
regulatory T cells after MART1 plasmid + AdMGshT were 
not significant compared to those of tumor-infiltrating 
immune cells, which provides the possibility that 
intratumoral injection can induce more rapid and potent 
immune activation in tumor site than in spleen.
One explanation as to why complete regression 
was not observed, even in the tumor tissue after treatment 
of MART1 plasmid + AdMGshT, may be that the innate 
immune response to oncolytic adenovirus inhibits the 
spread and persistence of the virus within tumors via 
tumor-infiltrating immune cells, such as M2 macrophages 
[56, 57]. Another possibility is that the increased release 
of IFN-γ from tumor-infiltrating immune cells (Figure 
7E) might have partially originated from the increase 
of antiviral effect, in addition to either T cell or NK cell 
activation, which eventually decreases the spreading of 
oncolytic adenovirus within tumors [57] and strengthens 
the gradual virus degradation (Figure 7F).
Taken together, these data imply that the 
combination of tumor antigen-specific induction via 
MART1, the non-specific immune stimulation via GM-
CSF, the shTGF-β2-mediated anti-tumor effects, and the 
oncolytic function of adenovirus was more potent than 
the anti-tumor effects of individual treatment (MART1 
or GM-CSF/shRNA of TGF-β2). Additionally, expected 
adverse effects such as autoimmune disease induced by 
excessive expression of multi-target genes can be strongly 
controlled by virus-oriented immune activation, resulting 
in multi genes-loaded oncolytic adenoviral degradation. 
Therefore, such combinations could be of use as better 
therapeutic strategies for controlling malignant melanoma.
MATERIALS AND METHODS
Cell culture
B16BL6 mouse melanoma cells were cultured in 
MEM with 10% fetal bovine serum FBS and MEM vitamin 
solution (HyClone, Logan, UT, USA). NIH-3T3 mouse 
embryo fibroblasts, B16F10 mouse melanoma cells, Lewis 
lung carcinoma (LLC) cells, and A375 human melanoma 
cells were cultured in DMEM with 10% FBS. Cells were 
maintained in a 37°C humidified atmosphere containing 5% 
CO2. Human melanoma SK-MEL-2, SK-MEL-3, and SK-
MEL28 cells and human embryonic kidney 293A cells were 
cultured in RPMI-1640 with 10% FBS and maintained in a 
37°C humidified atmosphere containing 5% CO2.
Reagents
Antibodies to phosphoAkt, phosphoSrc, 
phosphoSTAT3, and β-catenin were purchased from Cell 
Signaling Technology (Beverly, MA, USA). Antibodies 
to MART1, MelanA, CD8, and actin were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Antibodies to CD4, CD11b, CD25, NK1.1, IFN-γ and Ad5 
were purchased from Novus Biologicals (Littleton, CO, 
USA). Antibody to CD11b+c was purchased from Thermo 
Fisher Scientific (Waltham, MA, USA). Antibodies to 
CD3-FITC, CD4-PE/Cy7, CD25-APC, and CD11c were 
purchased from Abcam (Cambridge, UK). Antibodies to 
CD122-PE/Cy7, CD8a-APC, FoxP3-PE, and NK1.1-APC 
were purchased from Biolegend (San Diego, CA, USA). 
All other chemicals were purchased from Sigma-Aldrich 
(St Louis, MO, USA).
Construction of a stable cell line expressing CAR 
and E1B55KDa
After B16BL6 cells were transfected with a pIRES-
CAR/E1B55 plasmid expressing both the adenovirus 
receptor CAR and the adenovirus protein E1B55 [47], 
cells were cultured in MEM with 10% FBS, MEM vitamin 
solution, and 0.5 mg/ml G418 (Calbiochem, La Jolla, CA, 
USA) as selection medium, and the media was changed 
every 2–3 days after transfection. The positive cell clones 
that expressed both CAR and E1B55KDa protein were 
selected and named B16BL6-CAR/E1B55. B16BL6-CAR/
E1B55 cells were cultured in MEM with 10% FBS, MEM 
vitamin solution, and 0.5 mg/ml of G418, and cells were 
maintained in a 37°C humidified atmosphere containing 
5% CO2.
E1B-55 K polyclonal antibody production
A 25-mer synthetic peptide, MERRNPSERG 
VPAGFSGHASVESGC, from N-terminal of E1B-55K 
was selected among 5 candidates and conjugated to BSA 
as an immunogenic carrier protein and used to immunize 
two New Zealand White rabbits. The overall processes 
including antibody production and purification were 
performed by Young In Frontier (Seoul, Korea).
Construction of replication-deficient GFP 
adenoviral vectors
The enhanced green fluorescent protein (EGFP) 
gene, which originated from pEGFP-N1 (Clontech 
Laboratories, Mountain View, CA, USA), was cloned into 
the pCA14 vector via digestion with XhoI/XbaI. After 
linearization by XmnI digestion, the construct was co-
transformed into Escherichia coli BJ5183 together with 
the Bsp119I-digested adenoviral vector (dl324-BstBI, 
adenovirus vector with deleted E1 and E3 region) for 
homologous recombination. To verify the homologous 
recombination, plasmid DNA purified from overnight E. 
coli culture was digested with HindIII, and the digestion 
pattern was analyzed. The homologous recombinant 
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adenoviral plasmid DNA was digested with PacI and 
transfected into 293A cells to generate replication-
deficient adenovirus.
Construction of mouse TGF-β1 and TGF-β2 
shRNA
To construct mouse TGF-β1 shRNA, we 
screened eleven candidate sequences. Target selection 
was performed using an algorithm developed by 
Genolution Pharmaceuticals Inc. (Seoul, South Korea). 
The selected mouse TGF-β1 target sequence was 5’- 
CCCTCTACAACCAACACAACCCGGG-3’, and the 
loop sequence was 5’-TCTC-3’. To express mouse 
TGF-β1 shRNA in adenovirus, the top strand sequence 
(5’- GATC GCCTCTACAACCAACACAACCCGGGT
CTCCCCGGGTTGTGTTGGTTGTAGAGGGTTTT-3’) 
and the bottom strand sequence (5’-AGCTAAAA CCC
TCTACAACCAACACAACCCGGGGAGACCCGGG
TTGTGTTGGTTGTAGAGGG-3’) were annealed and 
subcloned into the pSP72ΔE3-U6 E3 shuttle vector, which 
was digested with BamHI and HindIII. The resulting 
adenoviral shuttle vector, pSP72ΔE3-U6-shTGF-β1, 
was linearized by XmnI digestion. The adenoviral vector 
dl324-IX was linearized by SpeI digestion, and the two 
linearized vectors were co-transformed into E. coli 
BJ5183 cells to undergo homologous recombination. 
The recombined adenoviral plasmids, dl324-IX-ΔE3-
U6-NC and dl324-IX-ΔE3-U6-shTGF-β1, were then 
digested with PacI and transfected into HEK-293 cells to 
generate the replication-incompetent adenovirus. For the 
construction of mouse TGF-β2 shRNA, target sequence 
(5’- GGATTGAACTGTATCAGATCCTTAA-3’) was 
selected from five candidate sequences, and the loop 
sequence was 5’-TCTC-3’. To express mouse TGF-β2 
shRNA in adenovirus, the top strand sequence (5’-GAT
CCGGATTGAACTGTATCAGATCCTTAATCTCTTA
AGGATCTGATACAGTTCAATCCTTTTA-3’) and the 
bottom strand sequence (5’-AGC TTAAAAGGATTGA
ACTGTATCAGATCCTTAAGAGATTAAGGATCTGA
TACAGTTCAATCCT-3’) were annealed and subcloned 
into the pSP72ΔE3-H1 vector. Then, the subsequent steps 
were performed as described for the production of mouse 
TGF-β1 shRNA-expressing adenovirus. The infectious 
titer of the adenovirus was determined by a limiting 
dilution assay in 293A cells.
Construction of oncolytic adenoviral vectors
For the construction of oncolytic adenovirus 
expressing shRNA of mTGF-β1 or mTGF-β2, pSP72ΔE3-
U6-shmTGFβ1 or pSP72ΔE3-H1-shmTGFβ2 was 
linearized by XmnI digestion and co-transformed into E. 
coli BJ5183 together with the SpeI-digested adenoviral 
vector (dl324-BstBI) for homologous recombination. The 
E1 shuttle vector was designed by subcloning HindIII-
blunt-BglII-digested pBSK[3484][58] into SspI-BglII-
digested pCA14 for mTGF-β1 to become pCA14-3484-
CMV-ΔE1B after replacement of the mouse survivin 
promoter with CMV promote by digestion with KpnI –
XhoI and removal of the E1B55 promoter-E1B55-SV40 
construct by an EcoRI-SalI blunt-ligation step. On the 
other hand, HindIII/EcoRI-digested pBSK[3484] was 
subcloned into HindIII/EcoRI-digested pVAX1 for the 
subcloning of mouse shRNA of TGF-β2. The E1R gene 
of adenovirus from StuI-blunt-EcoRI-digested pCA14 was 
inserted into ApaI-blunt-EcoRI-digested pVAX1-3484-
ΔE1B vector. The final E1 shuttle vector for oncolytic 
adenovirus was constructed after the mouse survivin 
promoter in pBSK[3484] was replaced with the CMV 
promoter from pVAX1-3484-CMV-ΔE1B-E1R through 
digestion with KpnI and XhoI. The E1 shuttle vector was 
linearized by PmeI digestion, and co-transformed into E. 
coli BJ5183 together with the BstBI-digested dl324-BstBI-
ΔE3-U6-shmTGFβ1 or BstBI-digested dl324-BstBI-
ΔE3-H1-shmTGFβ2 for homologous recombination. 
For the construction of oncolytic adenovirus expressing 
shRNA of mTGF-β1 and mTGF-β2 in the same construct, 
the U6-shmTGFβ1-SV40 construct from pSP72ΔE3-
U6-shmTGFβ1 was digested with SphI-blunt-KpnI 
and then subcloned into HindIII-blunt-KpnI-digested 
pSP72ΔE3-H1-shmTGFβ2 plasmid to yield pSP72ΔE3-
H1-shmTGFβ2-U6-shmTGFβ1. Then, dl324-BstBI-
H1-shmTGFβ2-U6-shmTGFβ1 was produced after the 
first homologous recombination followed by a second 
homologous recombination that resulted in generation 
of dl324-3484-ΔE3-H1-shmTGF-β2-U6-shmTGF-β1. 
For the expression of MART1, pVAX1-MART1, which 
was kindly provided by Dr. Butterfield (University of 
Pittsburgh, PA, USA), was used. The pMG-mGM-CSF, 
which was kindly provided by Dr. O'Sullivan (University 
College Cork, Ireland), was used for the subcloning of 
mGM-CSF. Each gene was subcloned into pIRES vector 
using NheI/MluI and XbaI/NotI, respectively. Then 
[CMVp-MART1-IRES], [CMVp-IRES-mGMCSF], 
and [CMVp-MART1-IRES-mGMCSF] constructs 
were subcloned into BglII/SalI-digested pVAX1-3484-
CMV-ΔE1B vector, and these plasmids were named 
pVAX1-3484-CMV-ΔE1B-MART1, pVAX1-3484-
CMV-ΔE1B-mGMCSF, and pVAX1-3484-CMV-ΔE1B-
MART1-IRES-mGMCSF, respectively. These E1 shuttle 
vectors were linearized by PmeI digestion and then co-
transformed into E.coli BJ5183 together with the Bsp119I-
digested dl324-BstBI or dl324-BstBI-ΔE3-U6-shmTGFβ2 
for homologous recombination, respectively.
Flow cytometric analysis
After B16BL6-CAR/E1B55 cells were infected with 
recombinant adenovirus for two days, infected cells were 
trypsinized and washed twice with ice-cold PBS. Then 
cells were incubated with anti-MART1 antibody for 1 h 
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at 4°C. After washing twice with ice-cold PBS, cells were 
incubated with Allophycocyanin (APC)-conjugated anti-
mouse IgG (BD Biosciences, Lincoln Park, NJ, USA) 
antibody in the dark for 45 min at 4°C. Cells were then 
washed twice with ice-cold PBS. As a negative control, 
mouse IgG fluorescence control (BD Biosciences) 
antibody was used. Finally, cells were suspended again 
in PBS and analyzed using a flow cytometer. For the 
detection of various immune cells after combination 
treatment of MART1 plasmid with AdMGshT, the following 
antibodies were used for staining: CD3-FITC, CD4-PE/
Cy7, CD25-APC (Abcam, UK), and CD122-PE/Cy7, 
CD8a-APC, Foxp3-PE, NK1.1-APC (Biolegend, USA). 
After adding the appropriate antibody, the cells were 
incubated in the dark at 4°C for 30 minutes and washed 
3 times by centrifugation using ice cold-PBS buffer, and 
then analyzed on a flow cytometer (Beckman Coulter, 
Inc., CA, USA). Data were analyzed by using FACSuit 
Software (BD, CA, USA).
CPE assay
To evaluate the CPE of several tumor-selective 
replication-competent adenoviruses, cells were first plated 
at approximately 80% confluence into the wells of a 48-
well tissue culture plate. The cells were then infected with 
replication-competent adenovirus at various MOIs. After 
24 h, cells were monitored daily by microscopy. When 
cells exhibited lysis at the lowest MOIs, remaining cells 
on the plate were fixed with 4% paraformaldehyde and 
stained with 0.05% crystal violet for analysis.
Non-radioactive cytotoxicity assay (LDH assay)
The activity of splenocytes was assessed via an 
LDH assay using the non-radioactive cytotoxicity assay 
kit (Promega, Madison, WI, USA). Cancer cells were 
incubated for 12 h in 48-well plates at 37°C under a 
humidified atmosphere of 5% CO2 and then co-cultured 
with splenocytes isolated from C57BL/6 mice for 4 h. For 
the LDH-positive control, cells were incubated for 45 min 
with 45 μl of lysis solution (10X) to lyse the cells. After 45 
min, the plates were centrifuged at 250 × g for 4 min, and 
then 50 μl of supernatant from each well was transferred 
to a fresh 96-well flat-bottom plate. A total of 50 μl of 
reconstituted Substrate Mix was added to each well of 
the plate, and the plate was then incubated for 30 min at 
room temperature in the dark. After 30 min, 50 μl of Stop 
Solution was added to each well, and the absorbance was 
recorded at 490 nm within 1 h using an ELISA plate reader 
(Molecular Devices Corporation, Sunnyvale, CA, USA). 
The percent cytotoxicity of adenovirus was calculated by 
the following formula:
% Cytotoxicity = ([experimental value - effector 
control value - negative control value] / [positive control 
value - negative control value])*100.
Real-time PCR
After B16BL6-CAR/E1B55 cells were infected with 
the recombinant adenovirus for 2 days, cells were lysed 
with the Trizol reagent (Life Technologies, Carlsbad, CA, 
USA), and the total RNA was isolated using chloroform. 
The RNA concentration was determined using the 
Nanodrop 2000 (Thermo Fisher Scientific). The real-time 
PCR reaction was performed using the Power SYBR Green 
RNA-to-CT 1-Step Kit (Life Technologies). The reaction 
mixture contained the reverse transcriptase enzyme 
mix, reverse transcription PCR mix, forward primer, 
reverse primer, RNA template, and nuclease-free water. 
Mouse TGF-β1 cDNA was amplified using the forward 
primer 5'- TTGCTTCAGCTCCACAGAGA -3' and the 
reverse primer 5'- TGGTTGTAGAGGGCAAGGAC -3'. 
Mouse TGF-β2 cDNA was amplified using the forward 
primer 5'-GTGAATGGCTCTCCTTCGAC-3' and the 
reverse primer 5'-CCTCGAGCTCTTCGCTTTTA-3'. 
Mouse TGF-β3 cDNA was amplified using the forward 
primer 5'- CTATCAGGTCCTGGCACTTT-3' and the 
reverse primer 5'- GGCAGATTCTTGCCACCTAT -3'. 
Mouse β-actin was amplified using the forward primer 
5'-GGCTGTATTCCCCTCCATCG-3' and the reverse 
primer 5'-CCAGTTGGTAACAATGCCATGT-3'.
ELISA
Cells were plated in the wells of six-well plates at 
2 × 105 cells/well and then infected with adenovirus (C, 
G, shT, GshT, or MGshT virus) at an MOI of 50. Infected 
cells were incubated for one more day after changing to 
serum-free medium after 24 h infection and the ELISA 
was performed after harvesting the medium. The levels of 
GM-CSF or TGF-β2 expression were determined by an 
ELISA according to the manufacturer’s instructions (R&D 
Systems, Minneapolis, MN, USA).
Murine spleen cell preparation
One week after the final injection of [pVAX1 
(control plasmid) or pVAX1-MART1 plasmid] or 
[pVAX1-MART1 plasmid with Ad or pVAX1-MART1 
plasmid with AdMGshT], C57BL/6 mice were sacrificed, and 
their spleens were extracted. After extraction, spleens and 
1 ml PBS were placed directly into a cell strainer in a petri 
dish. The spleens were mashed using the black rubber 
portion of the syringe, and splenocytes were released 
into the petri dish. The homogenized cell suspension 
was then washed two times with PBS. Splenocytes were 
resuspended in 4 ml PBS per spleen, and then ammonium 
chloride-based lysing reagent (BD Biosciences) was 
added. Cells were then incubated for 15 min in the dark at 
room temperature. Cells were washed two times with PBS 
and then resuspended in RPMI-1640.
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Animal studies
The animal protocol (2014-0335) used in this study 
was reviewed and approved by the Institutional Animal 
Care and Use Committee in Yonsei University Health 
System.
Tumors were implanted subcutaneously in the 
abdomens of C57BL/6 mice by injecting B16BL6-CAR/
E1B55 murine melanoma cells (7 x 105) in 100 μl of 
Hank’s balanced salt solution (HBSS; Gibco BRL). When 
tumors reached a range of 50-60 mm3, animals were 
randomized into four groups (PBS, Ad, AdG, and AdGshT) 
of 5 animals each. Adenovirus or PBS were administered 
intratumorally (virus; 1 x 109 plaque-forming unit (PFU) 
per tumor in 50 μl of PBS) on days 1, 3, and 5. Tumors 
were implanted subcutaneously in the abdomens of 
C57BL/6 mice by injecting B16BL6-CAR/E1B55 murine 
melanoma cells (7 x 105) in 100 μl of HBSS (Gibco BRL). 
After 4 days, C57BL/6 mice were injected intramuscularly 
in the rear quadriceps with 50 μg of pVAX1-MART1 
encoding MART1 (M) in a total volume of 50 μl saline 
using a 29-gauge needle. When tumors reached a range 
of 50-60 mm3, animals were randomized into 5 groups 
(M+PBS, M+Ad, M+AdM, M+AdGshT, and M+AdMGshT) 
of 5 animals each, and treatment was initiated. The first 
day of treatment was designated as day 1. Adenovirus or 
PBS was administered intratumorally (1 x 109 PFU per 
tumor in 50 μl of PBS) on days 1, 3, and 5. Regression of 
tumor growth was assessed by taking measurements of the 
length (L) and width (W) of the tumor. Tumor volume was 
calculated using the following formula: volume = 0.52 x 
L x W2.
Immunohistochemistry (IHC)
IHC studies were performed on paraffin-embedded 
tumor tissues using anti-CD4, anti-CD8, anti-NK1.1, 
anti-CD11b+c, anti-IFN-γ and anti-Ad5 antibodies to 
determine the expression of these proteins in the tumor 
tissues. The tumor tissue slides were deparaffinized by 
incubating in xylene for 10 min and rehydrated serially in 
alcohol (100%, 90%, and 70%). Endogenous peroxidase 
was blocked by incubation with 3% H2O2 for 15 min at 
room temperature, and antigen retrieval was achieved 
by incubating the slides in citrate buffer for 10 min in a 
steamer. For permeabilization, the slides were incubated 
in PBS containing 0.5% Triton X-100 for 30 min and then 
washed three times with PBS. To reduce non-specific 
background staining due to endogenous peroxidases, the 
slides were incubated with a hydrogen peroxide block 
(Thermo Scientific) for 10 min. After washing, an ultra 
V block (Thermo Scientific) was applied to the slides for 
5 min at room temperature to further block non-specific 
background staining. The slides were incubated with an 
anti-CD4 antibody (1:200 dilution), an anti-CD8 antibody 
(1:500), anti-NK1.1 antibody (1:500), anti-CD11b+c 
antibody (1:500), anti-IFN-γ antibody (1:200) and anti-
Ad5 antibody (1:800 dilution) for 12 h at 4°C and then 
further with a horseradish peroxidase polymer (Thermo 
Scientific) for 15 min at room temperature. To detect 
protein expression, the tissue sections were stained with 
diaminobenzidine tetrahydrochloride and minimally 
counterstained with hematoxylin (for visualization of 
antigen–antibody complexes). Sections were mounted 
under a coverslip using an aqueous mounting solution 
(Shandon Synthetic Mountant (Thermo Scientific) and 
xylene at a 1:1 ratio.
Confocal immunofluorescence staining
Immunofluorescence double staining was performed 
on paraffin-embedded tumor tissues using anti-CD4 
(Novus Biologicals, USA), anti-CD25 (Novus Biologicals, 
USA), anti-CD11c (Abcam, UK) and anti-CD11b (Novus 
Biologicals, USA) antibodies to determine the regulatory 
T cells and tolerogenic DC cells in the tumor tissues. The 
tumor tissue sections were deparaffinized by incubating 
xylene for 10 min and rehydrated serially in alcohol 
(100%, 90%, and 70%), and antigen retrieval was achieved 
by incubating the slides in citrate buffer for 10 min in a 
steamer. For permeabilization, the sections were incubated 
in PBS containing 0.5% Triton X-100 for 30 min and then 
washed three times with PBS. To reduce non-specific 
background staining the sections were incubated with 10% 
FBS for 1 hour in room temperature, and then incubated 
in 1st primary antibody (CD4, CD11c) at appropriate 
dilution (1:2000) in PBS for 20 min at room temperature. 
After washing with PBS containing 0.1% Tween-20 
for 3 times, the sections were incubated in flamma 
488-conjugated secondary antibody (1:1000) (BioActs, 
Korea) in PBS for 10 minutes at room temperature. After 
2nd blocking process, the sections were incubated in 2nd 
primary antibody (CD25, CD11b) at appropriate dilution 
(1:2000) in PBS for 1 hour at room temperature. After 
washing with PBS containing 0.1% Tween-20 for 3 times, 
the sections were incubated in flamma 552-conjugated 
secondary antibody (1:1000) (BioActs, Korea) in PBS 
for 10 minutes at room temperature. Finally, the sections 
were counterstained and coverslipped with DAPI-
Fluoromount-G (Aviva, San Diego, USA) for 20 minutes 
at room temperature to stain nuclei. Images were acquired 
using Confocal laser scanning microscope (Carl Zeiss, 
Jena, Germany).
Statistical analysis
The data were expressed as mean ± standard error 
(SE). Statistical comparison was made using SigmaPlot 
8.0 (Systat Software Inc., San Jose, CA, USA). P-values 
less than 0.05 were considered statistically significant (*, 
P<0.05; **, P<0.01; ***, P<0.001).
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